Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brahms' procalcitonin test:

This article was originally published in Clinica

Executive Summary

Brahms has received US 510(k) clearance of its procalcitonin (PCT) Kryptor test to assess patients' risk for severe sepsis and septic shock. The test, which provides results in less than an hour, will be used in critically ill patients in the intensive care unit to determine whether an infection is bacterial or viral. Bacterial infections can be treated quickly with antibiotics, while these drugs can be avoided in patients with viral infection (inappropriate use of antibiotics contributes to the increase in antibiotic-resistant bacteria). PCT levels are undetectable in healthy people, but bacterial infections cause levels to rise. This is not seen with viral infections. The first automated PCT test to reach the US market, bioMerieux's VIDAS B.R.A.H.M.S PCT test (licensed from Hennigsdorf, Germany-based Brahms in 2005), was approved in the US last October.

You may also be interested in...

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts